Abstract
Human pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer type with a very high mortality rate. Inflammatory cytokine such as tumor necrosis factor- alpha (TNF-α) plays a pivotal role in the progression of PDAC. Recently, suppression of cell invasion by preventive agents has received considerable attention in the prevention of metastatic tumors. Several clinical studies suggested that natural forms or analogues of fat-soluble vitamins such as vitamin A and vitamin D can work as anti-cancer agents to inhibit the development of cancer. In this study, our results demonstrated that co-treatment of 13-cis retinoic acid (13-cis RA) and 1,25-dihydroxyvitamin D3 (1,25-VD3) significantly inhibited TNF-α mediated cell invasion in PDAC in vitro. Cotreatment of 13-cis RA and 1,25-VD3 also inhibited TNF-α mediated expression of matrix metalloproteinase-9 (MMP-9) protein through blocking c-Jun N-terminal kinase (JNK) and nuclear factor kappa B (NF-κB) signaling pathways. Our results demonstrated that treatment of TNF-α lead to a decreased expression of tissue inhibitor of metalloproteinase- 3 (TIMP-3) protein and an induction of MMP-9 protein and cell invasion through an upregulation of microRNA-221 (miR-221) in human PDAC cells. Moreover, treatment of SP600125 (a specific inhibitor of JNK pathway) or cotreatment of 13-cis RA and 1,25-VD3 significantly induced a decreased expression of miR-221 and an increased expression of TIMP-3 protein. These results suggest that 13-cis RA and 1,25-VD3 significantly suppress TNF-α mediated cell invasion and therefore potentially act as preventive agents against PDAC.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / metabolism*
-
Adenocarcinoma / pathology
-
Anthracenes / pharmacology
-
Calcitriol / pharmacology*
-
Cell Line, Tumor
-
Cell Movement / drug effects*
-
Cell Movement / genetics
-
Cell Survival / drug effects
-
Cell Survival / genetics
-
Humans
-
Isotretinoin / pharmacology*
-
JNK Mitogen-Activated Protein Kinases / metabolism*
-
MAP Kinase Signaling System / drug effects*
-
MAP Kinase Signaling System / genetics
-
Matrix Metalloproteinase 9 / metabolism*
-
MicroRNAs / genetics
-
MicroRNAs / metabolism*
-
NF-kappa B / metabolism
-
Neoplasm Invasiveness
-
Pancreatic Neoplasms / metabolism*
-
Pancreatic Neoplasms / pathology
-
Phosphorylation / drug effects
-
Phosphorylation / genetics
-
Tissue Inhibitor of Metalloproteinase-3 / metabolism
-
Transfection
-
Tumor Necrosis Factor-alpha / pharmacology*
-
Up-Regulation / drug effects
-
Up-Regulation / genetics
Substances
-
Anthracenes
-
MIRN221 microRNA, human
-
MicroRNAs
-
NF-kappa B
-
TIMP3 protein, human
-
Tissue Inhibitor of Metalloproteinase-3
-
Tumor Necrosis Factor-alpha
-
pyrazolanthrone
-
JNK Mitogen-Activated Protein Kinases
-
MMP9 protein, human
-
Matrix Metalloproteinase 9
-
Isotretinoin
-
Calcitriol
Grants and funding
This research project is supported by the grant of Ministry of Science and Technology (MOST), Taiwan, under the agreements MOST-104-2320-B-039-041-MY3,107-2320-B-039-008-MY3, 103-2811-B-039-009, 105-2811-B-039-005,105-2811-B-039-031, 106-2811-B-039- 002, 106-2811-B-039-016, MOST 107-2320-B-005-003 -MY3, 107-2621-M-005-008 -MY3, 108-2321-B-005-004, China Medical University (CMU) grant under agreements CMU102-ASIA-23, CMU103-ASIA-20, CMU103-S-46, CMU104-S-32, Show Chwan Memorial Hospital grant under agreements SRD-109047, SRD-109048 and as well as in part by the Ministry of Education (MOE) Taiwan under the Higher Education Sprout Project at NCHU-IDCSA. Any results, conclusions, or implication described in this publication are from the author(s) of this manuscript and do not necessarily reflect the view of the MOST, MOE, Asia University, Show Chwan Memorial Hospital and CMU.